Sanofi's rotavirus vax hits late-stage trials; Sucampo, Takeda extend Amitiza pact;

@FiercePharma: Our newest special report is live! The top 10 most expensive drugs of 2013. Feature | Follow @FiercePharma

@EricPFierce: Artes, InstrAction, Q-Biologicals team up on virus-like particle (VLP) platform for vet vax. FierceAnimalHealth story | Follow @EricPFierce

@CarlyHFierce: Pictures tell the story in AstraZeneca's breast cancer photo-sharing push. FiercePharmaMarketing story | Follow @CarlyHFierce

> Sanofi's ($SNY) investigational rotavirus vaccine has entered Phase III trials in India. Release

> Sucampo and Takeda have extended their licensing agreement for constipation drug Amitiza. Release

> In a Phase III trial, patients with moderate-to-servere Hidradenitis suppurativa who received AbbVie's ($ABBV) Humira, beginning at week 4, achieved a statistically significant greater response compared with those on placebo. Release

> The U.K.'s cost-effectiveness gatekeeper has released the draft of guidance on medicines optimization that it hopes will be more patient-centered. Report

> Cancer experts have issued a 12-point code aimed at preventing up to half of all new cases of the disease in Europe. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Steris to buy Synergy for $1.9B in another med tech tax inversion deal. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: PAD patients gain another treatment option as the FDA approves its first drug-coated balloon. Story | Follow @VarunSaxena2

@EmilyWFierce: The top 10 most expensive drugs of 2013 range from $100K to upwards of $500K. Find out which ones made the list here. FiercePharma feature | Follow @EmilyWFierce

@MichaelGFierce: With Roche's Herceptin, green tea component doubles drug accumulation in cancer cells. FierceDrugDelivery story | Follow @MichaelGFierce

> AstraZeneca's $2B cancer contender lines up for EU scrutiny. More

> Stanford engineers develop pressure sensor that could lead to advances in prosthetics, medicine. Story

> Eye care Dx maker RPS receives $28M in debt financing from OrbiMed. Article

Biotech News

@FierceBiotech: Novartis joins an Atlas syndicate to back cancer drug upstart Raze. News | Follow @FierceBiotech

@JohnCFierce: Pharma VCs cluster behind a brainchild of UK biotech pioneer Sir Greg Winter. Report | Follow @JohnCFierce

@DamianFierce: NPR talks CRISPR with Berkeley's Jennifer Doudna, who happens to be a founder of Fierce 15 winner. More | Follow @DamianFierce

@EmilyMFierce: These 10 drugs could stop Ebola. Feature | Follow @EmilyMFierce

> Astellas dives into gene therapy with a Harvard expert in tow. Story

> AstraZeneca's $2B cancer contender lines up for EU scrutiny. More

> GW Pharma's cannabis-based drug comes up short in ulcerative colitis. Article

Biotech Research News

> Out-of-control neural stem cell growth may play part in autism. News

> HIV spikes reveal clues for vaccine development. Report

> Amicus drug improves Parkinson's symptoms in mice. Story

> Beta cells produced from stem cells could treat Type 1 diabetes. More

> Tetraphase antibiotic candidate kills gram-negative, resistant bacteria. Article

Pharma Manufacturing News

> Indian drugmakers scramble to prevent shortages of HIV/AIDS meds. Item

> FDA chastises Sun for weak follow-through on drug recalls. News

> Sources: Ranbaxy's key U.S. operations losing top dogs. More

> Mapp, HHS scrambling to find ways to supercharge production of Ebola drug. Story

> GSK adds jobs at North Carolina plant, expecting new drugs to take off. Article

And Finally... Janssen's Sirturo has won the UK Prix Galien Award for most innovative orphan drug.

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.